{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T19:05:33Z","timestamp":1784055933782,"version":"3.55.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T00:00:00Z","timestamp":1664496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T00:00:00Z","timestamp":1664496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"publisher","award":["20\/650"],"award-info":[{"award-number":["20\/650"]}],"id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Major depressive disorder (MDD) is a leading cause of disability worldwide. The current treatments are ineffective in approximately one-third of patients, resulting in a large economic burden and reduced quality of life for a significant proportion of the global population. There is considerable evidence that increased inflammation may distinguish a sub-type of MDD, and there are no validated diagnostic tools or treatments for neuroinflammation in MDD patients. The current study aims to explore the potential role of low-dose naltrexone (LDN), a drug with purported anti-inflammatory properties in the central nervous system, as an adjunctive treatment in patients with MDD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods\/design<\/jats:title><jats:p>This double-blind placebo-controlled hybrid parallel arm study enables the exploration of peripheral and central inflammatory markers with LDN as an approach to investigate inflammation as a pathophysiological contributor to MDD. Eligible participants with MDD (<jats:italic>n<\/jats:italic>= 48) will be stratified into the high and low inflammatory groups according to the levels of high-sensitivity C-reactive protein (hs-CRP) and then randomized to receive LDN or placebo for an initial 12 weeks, followed by a further 12 weeks during which all participants will receive LDN. The primary outcome measure will be the Montgomery-\u00c5sberg Depression Rating Scale (MADRS) administered at baseline, 2 weeks, 4 weeks, 8 weeks, 12 weeks, 14 weeks, 16 weeks, 20 weeks, and 24 weeks, to assess the effectiveness of the anti-depressant response. The secondary outcomes include the use of MRI techniques including quantitative magnetization transfer (qMT), echo-planar spectroscopic imaging (EPSI), and diffusion-weighted imaging (DWI) to help to elucidate the neurobiological mechanism of LDN, and the inflammatory mechanisms in action in MDD. Electroencephalography, blood samples, cognitive tasks, and additional questionnaires will also be used to determine if there is a specific profile of symptoms in individuals with inflammatory MDD. Healthy participants (<jats:italic>n<\/jats:italic>= 24) will be recruited for baseline outcome measures only, to enable comparison with patients with MDD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>This trial contributes to the literature on inflammation in MDD, including the understanding of the pathophysiology and efficacy of anti-inflammatory treatments. The investigation of inflammatory mechanisms in MDD is an important first step in the development of biomarkers to classify patient sub-groups, increase the accuracy of diagnosis, and tailor the approach to patients in clinical practice. This study may provide evidence of the benefit of LDN for the groups in whom conventional anti-depressants are ineffective and lead the way for translation into clinical practice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration<\/jats:title><jats:p>Australian New Zealand Clinical Trials Registry<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=383741&amp;isReview=true\">ACTRN12622000881730<\/jats:ext-link>. Registered on 21 June 2022<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13063-022-06738-3","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T23:04:02Z","timestamp":1664492642000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A randomized, double-blind, placebo-controlled, hybrid parallel-arm study of low-dose naltrexone as an adjunctive anti-inflammatory treatment for major depressive disorder"],"prefix":"10.1186","volume":"23","author":[{"given":"Julia R.","family":"Plank","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie C.","family":"Glover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben D.","family":"Moloney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas R.","family":"Hoeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick","family":"Sundram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael L.","family":"Sumner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh","family":"Muthukumaraswamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne C.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,30]]},"reference":[{"key":"6738_CR1","volume-title":"Depression","author":"World Health Organization","year":"2021","unstructured":"World Health Organization: Depression. (2021). https:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/depression. Accessed 7 Sept 2022."},{"key":"6738_CR2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.","edition":"5"},{"key":"6738_CR3","volume-title":"The economic cost of serious mental illness and comorbidities in Australia and New Zealand","author":"The Royal Australian and New Zealand College of Psychiatrists","year":"2016","unstructured":"The Royal Australian and New Zealand College of Psychiatrists. Global measures of prevalence of serious mental illness and associated premature mortality - a \u2018top-down\u2019 approach to estimating costs. In: The economic cost of serious mental illness and comorbidities in Australia and New Zealand: RANZCP; 2016. https:\/\/www.ranzcp.org\/files\/resources\/reports\/ranzcp-serious-mental-illness.aspx. Accessed 7 Sept 2022."},{"issue":"3","key":"6738_CR4","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/hup.288","volume":"16","author":"I Hindmarch","year":"2001","unstructured":"Hindmarch I. Expanding the horizons of depression: beyond the monoamine hypothesis. Hum Psychopharmacol. 2001;16(3):203\u201318. https:\/\/doi.org\/10.1002\/hup.288.","journal-title":"Hum Psychopharmacol"},{"issue":"1","key":"6738_CR5","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.it.2005.11.006","volume":"27","author":"CL Raison","year":"2006","unstructured":"Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006;27(1):24\u201331.","journal-title":"Trends Immunol"},{"issue":"10154","key":"6738_CR6","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/S0140-6736(18)32356-0","volume":"392","author":"E Bullmore","year":"2018","unstructured":"Bullmore E. The art of medicine: inflamed depression. Lancet. 2018;392(10154):1189\u201390. https:\/\/doi.org\/10.1016\/S0140-6736(18)32356-0.","journal-title":"Lancet"},{"key":"6738_CR7","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jad.2018.12.037","volume":"246","author":"R Strawbridge","year":"2019","unstructured":"Strawbridge R, Hodsoll J, Powell TR, Hotopf M, Hatch SL, Breen G, et al. Inflammatory profiles of severe treatment-resistant depression. J Affect Disord. 2019;246:42\u201351.","journal-title":"J Affect Disord"},{"key":"6738_CR8","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.bbi.2019.06.015","volume":"81","author":"D Enache","year":"2019","unstructured":"Enache D, Pariante CM, Mondelli V. Markers of central inflammation in major depressive disorder: a systematic review and meta-analysis of studies examining cerebrospinal fluid, positron emission tomography and post-mortem brain tissue. Brain Behav Immun. 2019;81:24\u201340.","journal-title":"Brain Behav Immun"},{"issue":"4","key":"6738_CR9","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.3892\/mmr.2016.4948","volume":"13","author":"WW Chen","year":"2016","unstructured":"Chen WW, Zhang X, Huang WJ. Role of neuroinflammation in neurodegenerative diseases. Mol Med Rep. 2016;13(4):3391\u20136.","journal-title":"Mol Med Rep"},{"issue":"5","key":"6738_CR10","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.biopsych.2009.03.007","volume":"66","author":"NA Harrison","year":"2009","unstructured":"Harrison NA, Brydon L, Walker C, Gray MA, Steptoe A, Dolan RJ, et al. Neural origins of human sickness in interoceptive responses to inflammation. Biol Psychiatry. 2009;66(5):415\u201322.","journal-title":"Biol Psychiatry"},{"issue":"1","key":"6738_CR11","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/nrn2297","volume":"9","author":"R Dantzer","year":"2008","unstructured":"Dantzer R, O\u2019Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9(1):46\u201356.","journal-title":"Nat Rev Neurosci"},{"issue":"1","key":"6738_CR12","first-page":"7","volume":"32","author":"M Maes","year":"2011","unstructured":"Maes M, Kubera M, Obuchowiczwa E, Goehler L, Brzeszcz J. Depression\u2019s multiple comorbidities explained by (neuro)inflammatory and oxidative & nitrosative stress pathways. Neuro Endocrinol Lett. 2011;32(1):7\u201324 PMID: 21407167.","journal-title":"Neuro Endocrinol Lett"},{"issue":"2","key":"6738_CR13","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1148\/radiographics.14.2.8190954","volume":"14","author":"RI Grossman","year":"1994","unstructured":"Grossman RI, Gomori JM, Ramer KN, Lexa FJ, Schnall MD. Magnetization transfer: theory and clinical applications in neuroradiology. Radiographics. 1994;14(2):279\u201390.","journal-title":"Radiographics"},{"issue":"1","key":"6738_CR14","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.biopsych.2014.09.023","volume":"78","author":"NA Harrison","year":"2015","unstructured":"Harrison NA, Cooper E, Dowell NG, Keramida G, Voon V, Critchley HD, et al. Quantitative magnetization transfer imaging as a biomarker for effects of systemic inflammation on the brain. Biol Psychiatry. 2015;78(1):49\u201357.","journal-title":"Biol Psychiatry"},{"issue":"2","key":"6738_CR15","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S0730-725X(02)00645-8","volume":"21","author":"A Ebel","year":"2003","unstructured":"Ebel A, Maudsley AA. Improved spectral quality for 3D MR spectroscopic imaging using a high spatial resolution acquisition strategy. Magn Reson Imaging. 2003;21(2):113\u201320.","journal-title":"Magn Reson Imaging"},{"issue":"4","key":"6738_CR16","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/cmr.1011","volume":"13","author":"RV Mulkern","year":"2001","unstructured":"Mulkern RV, Panych LP. Echo planar spectroscopic imaging. Concepts Magn Reson. 2001;13(4):213\u201337.","journal-title":"Concepts Magn Reson"},{"issue":"2","key":"6738_CR17","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1007\/s11682-018-0029-4","volume":"14","author":"C Mueller","year":"2020","unstructured":"Mueller C, Lin JC, Sheriff S, Maudsley AA, Younger JW. Evidence of widespread metabolite abnormalities in myalgic encephalomyelitis\/chronic fatigue syndrome: assessment with whole-brain magnetic resonance spectroscopy. Brain Imaging Behav. 2020;14(2):562\u201372.","journal-title":"Brain Imaging Behav"},{"issue":"1","key":"6738_CR18","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.neuroimage.2011.07.050","volume":"59","author":"J Zhuo","year":"2012","unstructured":"Zhuo J, Xu S, Proctor JL, Mullins RJ, Simon JZ, Fiskum G, et al. Diffusion kurtosis as an in vivo imaging marker for reactive astrogliosis in traumatic brain injury. Neuroimage. 2012;59(1):467\u201377.","journal-title":"Neuroimage"},{"issue":"1","key":"6738_CR19","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3109\/02699052.2014.947628","volume":"29","author":"JA Stokum","year":"2015","unstructured":"Stokum JA, Sours C, Zhuo J, Kane R, Shanmuganathan K, Gullapalli RP. A longitudinal evaluation of diffusion kurtosis imaging in patients with mild traumatic brain injury. Brain Injury. 2015;29(1):47\u201357.","journal-title":"Brain Injury"},{"key":"6738_CR20","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.neuroimage.2014.04.013","volume":"97","author":"SU Rudrapatna","year":"2014","unstructured":"Rudrapatna SU, Wieloch T, Beirup K, Ruscher K, Mol W, Yanev P, et al. Can diffusion kurtosis imaging improve the sensitivity and specificity of detecting microstructural alterations in brain tissue chronically after experimental stroke? Comparisons with diffusion tensor imaging and histology. Neuroimage. 2014;97:363\u201373.","journal-title":"Neuroimage"},{"issue":"6","key":"6738_CR21","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1007\/s00415-016-8118-z","volume":"263","author":"I de Kouchkovsky","year":"2016","unstructured":"de Kouchkovsky I, Fieremans E, Fleysher L, Herbert J, Grossman RI, Inglese M. Quantification of normal-appearing white matter tract integrity in multiple sclerosis: a diffusion kurtosis imaging study. J Neurol. 2016;263(6):1146\u201355.","journal-title":"J Neurol"},{"key":"6738_CR22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.pnpbp.2014.10.003","volume":"57","author":"HA Eyre","year":"2015","unstructured":"Eyre HA, Air T, Proctor S, Rositano S, Baune BT. A critical review of the efficacy of non-steroidal anti-inflammatory drugs in depression. Prog Neuropsychopharmacol Biol Psychiatry. 2015;57:11\u20136.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"8","key":"6738_CR23","doi-asserted-by":"publisher","first-page":"e00338","DOI":"10.1002\/brb3.338","volume":"5","author":"O K\u00f6hler","year":"2015","unstructured":"K\u00f6hler O, Petersen L, Mors O, Gasse C. Inflammation and depression: combined use of selective serotonin reuptake inhibitors and NSAIDs or paracetamol and psychiatric outcomes. Brain Behav. 2015;5(8):e00338.","journal-title":"Brain Behav"},{"issue":"12","key":"6738_CR24","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1001\/jamapsychiatry.2014.1611","volume":"71","author":"O K\u00f6hler","year":"2014","unstructured":"K\u00f6hler O, Benros ME, Nordentoft M, Farkouh ME, Iyengar RL, Mors O, et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry. 2014;71(12):1381\u201391.","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"6738_CR25","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1176\/ajp.131.6.646","volume":"131","author":"RB Resnick","year":"1974","unstructured":"Resnick RB, Volavka J, Freedman AM, Thomas M. Studies of EN-1639A (naltrexone): a new narcotic antagonist. Am J Psychiatry. 1974;131(6):646\u201350.","journal-title":"Am J Psychiatry"},{"issue":"7","key":"6738_CR26","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1007\/s10620-011-1653-7","volume":"56","author":"JP Smith","year":"2011","unstructured":"Smith JP, Bingaman SI, Ruggiero F, Mauger DT, Mukherjee A, McGovern CO, et al. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn\u2019s disease: a randomized placebo-controlled trial. Dig Dis Sci. 2011;56(7):2088\u201397.","journal-title":"Dig Dis Sci"},{"issue":"4","key":"6738_CR27","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1111\/j.1572-0241.2007.01045.x","volume":"102","author":"JP Smith","year":"2007","unstructured":"Smith JP, Stock H, Bingaman S, Mauger D, Rogosnitzky M, Zagon IS. Low-dose naltrexone therapy improves active Crohn\u2019s disease. Am J Gastroenterol. 2007;102(4):820\u20138.","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"6738_CR28","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s10067-014-2517-2","volume":"33","author":"J Younger","year":"2014","unstructured":"Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451\u20139.","journal-title":"Clin Rheumatol"},{"issue":"8","key":"6738_CR29","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1177\/1352458510366857","volume":"16","author":"N Sharafaddinzadeh","year":"2010","unstructured":"Sharafaddinzadeh N, Moghtaderi A, Kashipazha D, Majdinasab N, Shalbafan B. The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial. Mult Scler. 2010;16(8):964\u20139.","journal-title":"Mult Scler"},{"issue":"2","key":"6738_CR30","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/ana.22006","volume":"68","author":"BA Cree","year":"2010","unstructured":"Cree BA, Kornyeyeva E, Goodin DS. Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. Ann Neurol. 2010;68(2):145\u201350.","journal-title":"Ann Neurol"},{"issue":"4","key":"6738_CR31","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3390\/medsci6040082","volume":"6","author":"K Toljan","year":"2018","unstructured":"Toljan K, Vrooman B. Low-dose naltrexone (LDN)-review of therapeutic utilization. Med Sci (Basel). 2018;6(4):82. https:\/\/doi.org\/10.3390\/medsci6040082 PMID: 30248938; PMCID: PMC6313374.","journal-title":"Med Sci (Basel)"},{"issue":"1","key":"6738_CR32","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/j.1460-9568.2008.06321.x","volume":"28","author":"MR Hutchinson","year":"2008","unstructured":"Hutchinson MR, Zhang Y, Brown K, Coats BD, Shridhar M, Sholar PW, et al. Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4). Eur J Neurosci. 2008;28(1):20\u20139.","journal-title":"Eur J Neurosci"},{"issue":"2","key":"6738_CR33","first-page":"607","volume":"293","author":"B Liu","year":"2000","unstructured":"Liu B, Du L, Hong JS. Naloxone protects rat dopaminergic neurons against inflammatory damage through inhibition of microglia activation and superoxide generation. J Pharmacol Exp Ther. 2000;293(2):607\u201317 PMID: 10773035.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"6738_CR34","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1177\/1535370215596384","volume":"241","author":"LA Hammer","year":"2016","unstructured":"Hammer LA, Waldner H, Zagon IS, McLaughlin PJ. Opioid growth factor and low-dose naltrexone impair central nervous system infiltration by CD4+ T lymphocytes in established experimental autoimmune encephalomyelitis, a model of multiple sclerosis. Exp Biol Med. 2016;241(1):71\u20138.","journal-title":"Exp Biol Med"},{"issue":"9","key":"6738_CR35","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1258\/ebm.2011.011121","volume":"236","author":"RN Donahue","year":"2011","unstructured":"Donahue RN, McLaughlin PJ, Zagon IS. Low-dose naltrexone targets the opioid growth factor\u2013opioid growth factor receptor pathway to inhibit cell proliferation: mechanistic evidence from a tissue culture model. Exp Biol Med. 2011;236(9):1036\u201350.","journal-title":"Exp Biol Med"},{"issue":"2","key":"6738_CR36","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/art.37734","volume":"65","author":"J Younger","year":"2013","unstructured":"Younger J, Noor N, McCue R, Mackey S. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum. 2013;65(2):529\u201338.","journal-title":"Arthritis Rheum"},{"key":"6738_CR37","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jad.2016.08.029","volume":"208","author":"D Mischoulon","year":"2017","unstructured":"Mischoulon D, Hylek L, Yeung AS, Clain AJ, Baer L, Cusin C, et al. Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants. J Affect Disord. 2017;208:6\u201314.","journal-title":"J Affect Disord"},{"issue":"Suppl 13","key":"6738_CR38","first-page":"23","volume":"58","author":"ME Thase","year":"1997","unstructured":"Thase ME, Rush AJ. When at first you don\u2019t succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry. 1997;58(Suppl 13):23\u20139 PMID: 9402916.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"6738_CR39","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/biomedicines5020016","volume":"5","author":"L Parkitny","year":"2017","unstructured":"Parkitny L, Younger J. Reduced pro-inflammatory cytokines after eight weeks of low-dose naltrexone for fibromyalgia. Biomedicines. 2017;5(2):16.","journal-title":"Biomedicines"},{"issue":"1","key":"6738_CR40","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1192\/bjp.bp.106.032532","volume":"192","author":"JB Williams","year":"2008","unstructured":"Williams JB, Kobak KA. Development and reliability of a structured interview guide for the Montgomery Asberg Depression Rating Scale (SIGMA). Br J Psychiatry. 2008;192(1):52\u20138.","journal-title":"Br J Psychiatry"},{"key":"6738_CR41","volume-title":"Manual for the Beck Depression Inventory-II","author":"AT Beck","year":"1996","unstructured":"Beck AT, Steer RA, Brown GK. Manual for the Beck Depression Inventory-II. San Antonio: Psychological Corporation; 1996."},{"issue":"3","key":"6738_CR42","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s10862-006-9038-5","volume":"29","author":"JW Kanter","year":"2007","unstructured":"Kanter JW, Mulick PS, Busch AM, Berlin KS, Martell CR. The Behavioral Activation for Depression Scale (BADS): psychometric properties and factor structure. J Psychopathol Behav Assess. 2007;29(3):191\u2013202.","journal-title":"J Psychopathol Behav Assess"},{"key":"6738_CR43","volume-title":"Manual for the profile of mood states (POMS)","author":"D McNair","year":"1971","unstructured":"McNair D, Lorr M, Droppleman L. Manual for the profile of mood states (POMS). San Diego: Educational and Industrial Testing Service; 1971."},{"issue":"1","key":"6738_CR44","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/PSY.0000000000000534","volume":"80","author":"GM Slavich","year":"2018","unstructured":"Slavich GM, Shields GS. Assessing lifetime stress exposure using the Stress and Adversity Inventory for Adults (Adult STRAIN): an overview and initial validation. Psychosom Med. 2018;80(1):17.","journal-title":"Psychosom Med"},{"issue":"6","key":"6738_CR45","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware Jr","year":"1992","unstructured":"Ware JE Jr, Sherbourne CD. The MOS 36-Item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473\u201383 PMID: 1593914.","journal-title":"Med Care"},{"issue":"11","key":"6738_CR46","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1177\/1359105316659917","volume":"23","author":"A Andreasson","year":"2018","unstructured":"Andreasson A, Wicksell RK, Lodin K, Karshikoff B, Axelsson J, Lekander M. A global measure of sickness behaviour: development of the Sickness Questionnaire. J Health Psychol. 2018;23(11):1452\u201363.","journal-title":"J Health Psychol"},{"issue":"11 Supplement 3","key":"6738_CR47","doi-asserted-by":"publisher","first-page":"S54","DOI":"10.1212\/WNL.0b013e3182872ded","volume":"80","author":"S Weintraub","year":"2013","unstructured":"Weintraub S, Dikmen SS, Heaton RK, Tulsky DS, Zelazo PD, Bauer PJ, et al. Cognition assessment using the NIH Toolbox. Neurology. 2013;80(11 Supplement 3):S54\u201364.","journal-title":"Neurology"},{"issue":"4","key":"6738_CR48","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/psyp.12370","volume":"52","author":"GH Proudfit","year":"2015","unstructured":"Proudfit GH. The reward positivity: from basic research on reward to a biomarker for depression. Psychophysiology. 2015;52(4):449\u201359.","journal-title":"Psychophysiology"},{"issue":"1","key":"6738_CR49","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1080\/03036758.2020.1780274","volume":"51","author":"IJ Kirk","year":"2021","unstructured":"Kirk IJ, Spriggs MJ, Sumner RL. Human EEG and the mechanisms of memory: investigating long-term potentiation (LTP) in sensory-evoked potentials. J R Soc N Z. 2021;51(1):24\u201340.","journal-title":"J R Soc N Z"},{"key":"6738_CR50","doi-asserted-by":"publisher","first-page":"116098","DOI":"10.1016\/j.neuroimage.2019.116098","volume":"202","author":"LJ Balter","year":"2019","unstructured":"Balter LJ, Bosch JA, Aldred S, Drayson MT, van Zanten JJ, Higgs S, et al. Selective effects of acute low-grade inflammation on human visual attention. NeuroImage. 2019;202:116098.","journal-title":"NeuroImage"},{"issue":"4","key":"6738_CR51","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/pds.2067","volume":"20","author":"W Rief","year":"2011","unstructured":"Rief W, Barsky AJ, Glombiewski JA, Nestoriuc Y, Glaesmer H, Braehler E. Assessing general side effects in clinical trials: reference data from the general population. Pharmacoepidemiol Drug Saf. 2011;20(4):405\u201315. https:\/\/doi.org\/10.1002\/pds.2067 Epub 2010 Nov 8. PMID: 21442687.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"6738_CR52","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1177\/1740774512465064","volume":"9","author":"J Younger","year":"2012","unstructured":"Younger J, Gandhi V, Hubbard E, Mackey S. Development of the Stanford Expectations of Treatment Scale (SETS): a tool for measuring patient outcome expectancy in clinical trials. Clin Trials. 2012;9(6):767\u201376.","journal-title":"Clin Trials"},{"key":"6738_CR53","volume-title":"Medicines regulations 1984","author":"D Beattie","year":"2022","unstructured":"Beattie D. Part 7: prescription. In: Medicines regulations 1984: Parliamentary Counsel Office; 2022. https:\/\/www.legislation.govt.nz\/regulation\/public\/1984\/0143\/latest\/DLM95668.html. Accessed 17 Aug 2022."},{"issue":"1","key":"6738_CR54","first-page":"45","volume":"5","author":"RL Sumner","year":"2020","unstructured":"Sumner RL, McMillan R, Spriggs MJ, Campbell D, Malpas G, Maxwell E, et al. Ketamine enhances visual sensory evoked potential long-term potentiation in patients with major depressive disorder. Biol Psychiatry Cogn Neurosci Neuroimaging. 2020;5(1):45\u201355.","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"issue":"2","key":"6738_CR55","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377\u201381.","journal-title":"J Biomed Inform"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06738-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-022-06738-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06738-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T04:32:49Z","timestamp":1701145969000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-022-06738-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,30]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["6738"],"URL":"https:\/\/doi.org\/10.1186\/s13063-022-06738-3","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,30]]},"assertion":[{"value":"21 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial protocol (version 2 dated 19 May 2022) has been approved by the Southern Health and Disability Ethics Committee on 14 June 2022, approval number 12781. Written informed consent will be received from each study participant by the study team prior to admittance into the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Participants provided informed consent for the use of their de-identified data in publications.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"822"}}